Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 6/20 | 0.68 |
| ▸ | KISS1R | Q969F8 | 12/20 | 0.63 |
| ▸ | GHSR | Q92847 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29419957 | 0.95 | MC4R (0.63) | MC4RKISS1RGHSR | |
| SCHEMBL22117389 | 0.93 | KISS1R (0.61) | MC4RKISS1RGHSR | |
| SCHEMBL22117388 | 0.93 | KISS1R (0.61) | MC4RKISS1RGHSR | |
| SCHEMBL12094803 | 0.93 | MC4R (0.62) | MC4RKISS1R | |
| SCHEMBL12094778 | 0.93 | MC4R (0.62) | MC4RKISS1R | |
| SCHEMBL12094740 | 0.93 | MC4R (0.62) | MC4RKISS1R | |
| SCHEMBL12094763 | 0.93 | MC4R (0.62) | MC4RKISS1R | |
| SCHEMBL12094761 | 0.93 | MC4R (0.62) | MC4RKISS1R | |
| SCHEMBL28058268 | 0.93 | MC4R (0.60) | MC4RKISS1RGHSR | |
| SCHEMBL28058267 | 0.93 | MC4R (0.60) | MC4RKISS1RGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711004-A2 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2025-06-19 | — | — | US | disclosed |
| WO-2025106751-A1 | COMBINATIONS OF A POTASSIUM CHANNEL ACTIVATOR AND AN MC4R AGONIST AND RELATED METHODS OF USE | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12263202-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240058414-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4216979-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4029513-A1 | MELANOCORTIN-4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISORDERS CHARACTERISED BY POMC GENE HYPERMETHYLATION | Rhythm Pharmaceuticals, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3988108-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | Rhythm Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022067086-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058414-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | MC4R 1/4885KISS1R 545/4885GHSR 29/4885 |
| US-12263202-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | MC4R, MC5R, MC3R | MC4R 1/4885KISS1R 487/4885GHSR 35/4885 |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | MC4R 1/4885KISS1R 75/4885GHSR 15/4885 |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | MC4R 1/4885KISS1R 487/4885GHSR 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.